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Background: Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from
luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still
unknown and need to be investigated.
Methods: 305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively
followed up.
Results: In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic
sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with
luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it
could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax
was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.
Conclusions: SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype
may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype,
does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic
disease of luminal subtype.
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Breast cancer is the most common female cancer. It
affects almost 1.4 million women worldwide and about
459,000 patients die due to this disease every year [1].
Approximately 6% of women with breast cancer have
metastatic disease at the time of diagnosis and about
20% of patients initially diagnosed with localized disease
will develop metastatic breast cancer (MBC) [2]. Despite
significant improvements in the treatment of MBC* Correspondence: huxicun@gmail.com
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reproduction in any medium, provided the orduring the last decade, it remains an incurable disease,
with a median life expectancy of 18–30 months [3].
Hormone receptors (HR), estrogen receptor (ER) and
progesterone receptor (PgR), play important roles in
breast cancer development, progression and response to
therapy. The traditional classification of breast cancers
into HR-positive and -negative groups helps to guide
patient management. However, despite appropriate endo-
crine therapy, some HR-positive tumors recur and/or be-
come metastatic. Microarray gene expression analysis
(cDNA) has identified two biologically distinct HR-
positive subtypes of breast cancer with significant
differences in patient outcome: luminal A and luminal B
[4]. However, cDNA analysis is too complex and costly
and thus not routinely performed to identify breast cancerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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obtained by immunohistochemical (IHC) analysis of the
tumor expression of ER, PgR, HER2 or Ki67 [5]. IHC
could also classify two categories of luminal subtypes: lu-
minal A (ER and/or PgR-positive, HER2-negative), and lu-
minal B (ER and/or PgR-positive, HER2-positive) [5].
However, compared to cDNA array, the IHC testing does
not identify all the luminal B tumors because only 30% to
50% are HER2-positive on IHC. Thus, many luminal B
tumors on cDNA array would be classified as luminal A
on IHC. In 2009, Cheang et al. modified the IHC defin-
ition and found that Ki67 could distinguish on IHC the
luminal A versus B subtype more accurately, with the
Ki67 index cut point of 13.25% [6]. The luminal A subtype
was then defined as HR-positive, HER2-negative breast
cancer with Ki67 index < 14%, while luminal B subtype
was defined as also HR-positive, but either HER2-positive,
or HER2-negative with Ki67 index ≥ 14%. Compared with
luminal A tumors, luminal B tumors have thus higher
proliferation and poorer outcomes despite being clinically
HR-positive. Consequently, the major biological distinc-
tion between luminal A and B is the proliferation sig-
nature, which includes genes such as CCNB1, MKI67, and
MYBL2, with higher expression in luminal B than in
luminal A tumors and may be important to breast cancer
biology and prognosis [7,8].
Positron emission tomography (PET), using the radio-
labeled glucose analog 18 F-fluorodeoxyglucose (18 F-FDG),
can detect enhanced glycolysis of cancer cells and has
proven valuable in diagnosing, staging, detecting recur-
rences, and assessing response to therapy in a multitude of










Eligible patients (n= 13
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underwent PET/CT and 
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Figure 1 Patient screening and inclusion diagram.usually indicates the degree of tumor proliferation and
metabolism, it was felt important to evaluate whether PET
could be used as a noninvasive diagnostic modality to dif-
ferentiate luminal A from luminal B tumors and hence
predicting their behavior and prognosis. The standardized
uptake value (SUV) is a semi-quantitative simplified meas-
urement of the tissue FDG accumulation rate, and studies
of the head and neck, lung, esophageal, endometrial,
cervical and renal cell cancer have explored the prognostic
significance of the maximum standardized uptake value
(SUVmax) [10-16]. However, the role of the Baseline
SUVmax as a prognostic factor for treatment naïve MBC
patients of luminal subtype has not yet been evaluated so far.
The main objective of this study was to determine
whether Baseline SUVmax in MBC patients correlates
with validated prognostic markers and their luminal
subtypes, and to establish whether the Baseline SUVmax
could be used as a noninvasive indicator to differentiate
luminal A from luminal B subtypes. In addition, we
also prospectively investigated the impact of Baseline
SUVmax on the survival of MBC patients with luminal
subtype.
Methods
Study design and patient population
Between February 2007 until December 2010, a total of
305 MBC patients with luminal subtypes (HR-positive)
signed consent for this study and underwent PET/CT
examinations. Baseline information collected, including
PET/CT results, was then used to evaluate whether the
individual was eligible for the study according to inclu-
sion and exclusion criteria (Figure 1). Eligible patientsbtypes (n = 305)
ded (n = 152)
ith history of diabetes mellitus
ith a second primary cancer diagnosed
ith ECOG 3 and life expectancy < 3 months
ith previous treatment in metastatic setting
ith no evaluable lesions documented 
by abnormal FDG uptake
rew the consent (n = 19)
4)
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in Fudan University Shanghai Cancer Center (FUSCC),
Shanghai, China. This study was approved by the FUSCC
institutional ethical review board.
Originally we defined the luminal subtypes as defined
by Carey et al. [5]. After 2009, we changed the diagnostic
criteria and reviewed all the paraffin sections before.
The new criteria were described according to ER, PgR,
HER2 and Ki67 status [6]. We defined HR-positive,
HER2-negative and Ki67 index <14% as luminal A, HR-
positive and HER2-positive (or HER2-negative with Ki67
index ≥14%) as luminal B. Her-2/Neu status was defined
positive when over-expressed with 3 plus staining in IHC
or amplified with a ratio > 2.2 by fluorescence in situ
hybridization (FISH). Ki67 was visually scored for percent-
age of tumor cell nuclei with positive immunostaining
above the background level by two pathologists.
Criteria for inclusion were as follows: female gender, 18 to70
years of age, histologically confirmed breast cancer with lu-
minal subtypes, eastern cooperative oncology group (ECOG)
performance status of 0 to 2, life expectancy of > 3 months,
written informed consent for the study participation, ad-
equate bone marrow reserve, adequate liver and renal
function, with no systemic or locoregional therapy in the
metastatic setting, and at least one evaluable metastatic le-
sion with abnormal FDG uptake.
Exclusion criteria included: uncontrolled brain metas-
tasis, pregnancy or breast-feeding, history of diabetes
mellitus, diagnosis of second primary malignancy, and
active or uncontrolled infection.
18 F-FDG PET, image analysis and information collection
18 F-FDG was produced automatically by cyclotron
(Siemens CTI RDS Eclips ST) using Explora FDG4™
module at our single institution. PET/CT was performed
using a PET/CT system (Siemens biograph 16HR). All
patients were instructed to fast for at least 6 hours be-
fore PET imaging. At the time of the tracer injection,
patients should have had a blood glucose level of less
than 7.8 mmol/L. Before and after injection, patients
were kept lying comfortably in a quiet, dimly lit room.
There was no significant difference in blood glucose levels
measured at the time of the pre- and post-18 F-FDG stud-
ies. Image acquisition was started 1 h ± 10 min after intra-
venous administration of FDG (7.4 MBq/kg body weight).
For the semi-quantitative analysis, a volume of interest
(VOI) was drawn with a multimodality computer plat-
form (Siemens) for each lesion with the largest uptake
according to size and intensity. Tumor size had to be a
minimum of 1 cm to minimize partial volume averaging
effects in FDG-PET interpretation. Interpretation of the
PET/CT images was based on assessment of the focal
FDG uptake and a quantitative evaluation by calculating
the SUVmax for each lesion instead of using the meanSUV of the lesion, which was more operator-dependent.
Two nuclear medicine - CT diagnostic radiologists with
at least 5 years of experience and unaware of the clinical
information analyzed the data independently, and a third
similarly qualified physician was asked for opinion in
cases of discordance. The lesions with positive 18 F-FDG
uptake were biopsied (n = 55, including 27 fine needle
aspirations and 28 core biopsies), or assessed by further
imaging and clinical follow-up (n = 79) to establish ma-
lignant characteristics.
Baseline information of the cohort including SUVmax
and molecular subtypes was collected. For patients who
had multiple metastatic sites, the single lesion with the
highest SUVmax was used for calculation. All the infor-
mation of molecular classification was obtained from the
initial tumor sample from the primary surgery, with
evaluation of patients’ tumor status performed using
Response Evaluation Criteria in Solid Tumors (RECIST)
v1.0 criteria. All patients were followed up at two-month
intervals, and the data were collected and updated until
February 25, 2012. Relapse-free interval (RFI) was
defined as the interval between primary tumor and re-
currence. Progression-free survival (PFS) was defined as
the length of time from the date of the informed consent
to disease progression or death from any cause. Overall
survival (OS)1 was defined as the interval between the
date of breast surgery and the date of death from any
cause. OS2 was defined as the time from the date of the
informed consent until the date of death from any cause.Statistical methodology
We present summary statistics for SUVmax as medians
and interquartile ranges (IQRs), because data were not
normally distributed (data not shown). The impact of
different clinical parameters including luminal types on
Baseline SUVmax was evaluated by Mann–Whitney U
test (between 2 groups) or Kruskal-Wallis test ( ≥ 3 groups).
Receiver operator characteristic (ROC) curves were used to
identify potential SUV cutoffs predictive of different luminal
subtype. An area under the curve of 1.0 would indicate a
perfect test, whereas 0.5 would represent a noninformative
test. Kaplan-Meier method was accessed for survival ana-
lysis. Prognostic variables identified by univariate analysis,
with P < 0.1, were analyzed in the multivariate Cox model.
All reported p-values were two-sided. Statistical significance
levels were set at P < 0.05. Statistical analyses were per-
formed with SPSS 16.0 (SPSS, Chicago, IL).Results
Patient and tumor characteristics
Overall, 305 MBC patients with luminal subtypes signed
informed consent documents and underwent screening
consecutively, of whom 134 were eligible for this study
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range, 28–74 years) (Figure 1). The median time from
diagnosis of primary disease to MBC diagnosis was 32.1 -
months (range, 0.5–245.9 months), and most patients
(64.2%) relapsed after 2 years. Out of all eligible patients,
75 (56.0%) were luminal A type, 59 (44.0%) were luminal
B type. Visceral metastases were present in 70 patients
(52.2%) and non-visceral metastases included only lymph
node involved (13.4%), only bone involved (14.9%), only
skin and soft tissue involved (3.7%), and mixed (20.1%).
Before the PET/CT procedure, 2 patients (1.5%) did not
receive any systemic treatment, 4 (3.0%) received adju-
vant or neoadjuvant (adj/neo) chemotherapy only, 6
(4.5%) received adj/neo hormonal therapy only, 101
(75.4%) received adj/neo chemotherapy plus hormonal
therapy, and 21 (15.7%) received regimens including
targeting agents in the adj/neo setting. Other baseline
characteristics are provided in Table 1. The median follow-
up time of this cohort after inclusion was 26.6 months
(range, 14.17–51.2 months).
Factors associated with baseline SUVmax
The current study evaluated the influence of age, men-
struation status, tumor histology, luminal subtype, type
of neo/adjuvant therapy, RFI, number of metastatic sites,
and visceral metastasis on Baseline SUVmax with
Mann–Whitney U test or Kruskal-Wallis test. If patients
had multiple metastatic lesions, the maximum one of
SUVmax values of these lesions was selected for statis-
tical analysis. The results showed that SUVmax was sig-
nificantly higher only in patients with more metastatic
sites (P = 0.002) or with presence of visceral metastasis
(P = 0.009). In patients without visceral metastases,
SUVmax of patients with bone involved only had a trend
to be lower than the others (P = 0.063) (Table 1).
Evaluation of baseline SUVmax to differentiate luminal
subtypes
The ROC curve was obtained by plotting a graph, in
which the vertical axis showed sensitivity and the hori-
zontal axis showed the false-positive rate. The area
under ROC curve was 0.516 (SE 0.052) (SE is the stand-
ard error of the area estimate), which indicated that the
Baseline SUVmax in the metastatic setting did not ef-
fectively separate patients with luminal A subtype from
those with luminal B subtype (Figure 2).
Baseline SUVmax and luminal subtypes as prognostic
variables
All patients in the study experienced disease relapse and
developed metastases after primary breast surgery. Univariate
analysis showed that luminal subtype was significantly
associated with RFI (P < 0.001) and OS1 (P = 0.011), but not
with PFS (P = 0.550) or OS2 (P = 0.233) (Table 2 andFigure 3A-D). Age, menstruation status, and tumor histology
had no significant effect on PFS and OS2.
The univariate analysis also indicated that RFI ≤ 2 years
(P = 0.003 and P = 0.017, respectively), more metastatic
sites (P = 0.002 and P = 0.032, respectively), presence of
visceral metastasis (P = 0.035 and P = 0.393, respect-
ively), chemotherapy as the first-line therapy after PET/
CT (P = 0.037 and P=0.019, respectively) and higher
Baseline SUVmax (P = 0.002 and P = 0.009, respectively;
Figure 3E-F) were significantly associated with shorter
PFS and OS2 (Table 2). Here, the patients with different
SUVmax were classified into three groups based on
tertiles of SUVmax. Tertiles (as opposed to quartiles,
quintiles, etc.) were chosen to balance the flexibility
gained by adding more groups with the need to keep
group sizes sufficiently large for subgroup analyses.
Cox regression analysis showed that Baseline SUVmax,
RFI, and number of metastatic sites were three inde-
pendent prognostic factors for PFS, while the significant
predictors of OS2 in the regression model were Baseline
SUVmax and RFI. Hazard ratios (HRs) for these
factors are reported in Table 3. The significant prog-
nostic effect of SUVmax on PFS and OS was
maintained after correcting for tumor phenotype and
variables with P < 0.1 on univariate analysis. By using the
tertile with the lowest SUVmax as the reference group,
patients in the highest tertile of SUVmax had the shortest
PFS (HR = 2.06; 95% CI, 1.23-3.45) and OS (HR = 3.54;
95% CI, 1.66-7.55).
Discussion
Given the fact that human breast cancer depends on HR
signaling in regards to response to endocrine therapies,
breast cancers have traditionally been sub-classified into
HR-positive (or “luminal”) and HR-negative diseases. As
identified, even the HR-positive or luminal cancers com-
prise a spectrum of tumors with varying degrees of
proliferation and levels of genetic aberrations. Thus, “lu-
minal type” of HR positive tumors can be further divided
into subclass A and B with luminal B being higher grade,
having higher proliferation index and a poorer prognosis
independent on hormonal therapy. Since a significant
correlation between FDG uptake in breast cancer by
PET scan and proliferation index has been observed
[17], and the tumor proliferation, as defined by
microarray-based gene signatures or Oncotype DX
testing (the 21 gene assay, Genomic Health), has been
shown to be one of the strongest predictors of outcome
for patients with HR-positive disease [18], it was import-
ant to establish whether SUVmax as identified by PET
scanning could noninvasively differentiate luminal A
from luminal B tumors, and whether SUVmax could
predict the outcome of MBC patients with luminal
subtypes.
Table 1 Patient characteristics and SUVmax comparisons between or among groups
Characteristics No. of patients
(n=134)
Baseline SUVmax
Median IQR P value*
Age
≤ 50 63 (47.0%) 6.60 5.10–9.10 0.616
> 50 71 (53.0%) 6.85 4.80–9.80
Menstruation status
Pre-menopausal 53 (39.6%) 6.60 5.10–9.00 0.685
Post-menopausal 81 (60.4%) 6.85 4.85–9.75
Histology
IDC 124 (92.5%) 6.95 5.03–9.66 0.131
ILC 6 (4.5%) 6.33 5.15–9.90
Others 4 (3.0%) 4.65 3.10–5.68
Luminal subtype
Luminal A 75 (56.0%) 6.75 5.10–9.20 0.744
Luminal B 59 (44.0%) 7.00 4.80–10.00
Adjuvant/neoadjuvant therapy
Only CT (± RT) 4 (3.0%) 6.68 5.76–9.05 0.887
Only HT (± RT) 6 (4.5%) 6.15 3.74–9.85
CT + HT (± RT) 101 (75.4%) 6.75 5.15–9.25
Therapy with TT 21 (15.7%) 7.00 4.75–10.25
No 2 (1.5%) 5.50 4.50–6.50
Relapse-free interval
≤ 2 years 48 (35.8%) 6.25 4.81–9.20 0.592
> 2 years 86 (64.2%) 7.00 5.18–9.59
No. of metastatic sites
1 53 (39.6%) 6.10 4.60–9.08 0.002
2 37 (27.6%) 6.25 4.70–8.15
≥ 3 44 (32.8%) 8.40 6.21–10.73
Visceral metastasis
Yes 64 (47.8%) 7.60 5.53–10.28 0.009
No 70 (52.2%) 6.32 4.80–7.73
Only bone 20 (14.9%) 4.85 3.58–7.10 0.063
Others
Only lymph node 18 (13.4%) 6.37 5.20–7.78
Only skin & soft tissue 5 (3.7%) 10.1 4.45–10.30
Mixed 27 (20.1%) 6.70 5.10–7.70
SUVmax: the maximum standardized uptake value; No.: number; IQR: interquartile range; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; CT:
chemotherapy; RT: radiotherapy; HT: hormonal therapy; TT: target therapy.
* Mann–Whitney U test (between 2 groups) or Kruskal-Wallis test (≥3 groups).
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after relapse may provide important information about
tumor proliferation and metabolism that could be of prog-
nostic significance. In this regard, a study of the associ-
ation of Baseline SUVmax with other well-established
prognostic factors could be an important first step to-
wards establishing the relevance of FDG-PET in the prog-
nostic characterization of MBC. Our study found thatBaseline SUVmax of MBC was significantly associated
only with number of metastatic sites and presence of vis-
ceral metastasis. This finding could be the result of
accelerated glucose metabolism and related increased
metabolic activity of those more aggressive metastatic
tumor phenotypes. However, the location of metastatic le-
sion could also influence the SUVmax. For example, bone
metastasis of breast cancer is often osteoblastic and
Figure 2 The receiver operator characteristic (ROC) curve for
SUVmax in the differential diagnosis of luminal A subtype from
luminal B subtype. The curve describes the association between
sensitivity and specificity at different thresholds. The area under the
curve (AUC) was 0.516.
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uptake, regardless of biologic behavior of tumor cells. In
patients with visceral metastases (± non-visceral metasta-
ses) of this study, almost all the SUVmax were obtained
from visceral lesions. Only in patients without visceral me-
tastases, the assessment of influence on SUVmax by meta-
static locations such as bone, lymph node, skin or soft
tissue might be important. However, we did not find any
significant differences among these locations (P = 0.235),
even between patients with bone involved only and the
others (P = 0.063) in terms of median SUVmax.
Our further investigation using the ROC curve
indicated that the Baseline SUVmax in the metastatic
setting could not differentiate luminal A from luminal B
subtypes effectively. This might be because the differ-
ence between luminal A and B tumors in proliferation
and metabolism was not substantial enough to influence
SUVmax. Therefore, the SUVmax cannot be used as a
noninvasive indicator to differentiate luminal A from lu-
minal B subtypes. However, it should be noted that the
association between Baseline SUVmax and luminal
subtypes may be confounded by the fact that relapsed or
metastatic lesions may have a different HR or HER2 sta-
tus from that of the primary tumor [19-24] and that core
biopsies in our study were performed only in a small
proportion of patients at the time of relapse. Thus, in
order to clarify whether SUVmax will have a role in lu-
minal subtypes differentiation, it may be necessary toconduct another large-sample study to correlate SUVmax
with core biopsies of the PET scan tested metastatic
lesions. However, from 28 patients with core biopsies in
our study, only 14.3% had discordant molecular subtypes
with the primary lesions (Additional file 1: Figure 1).
When Baseline SUVmax was used to differentiate the lu-
minal subtypes after relapse in these patients, the area
under ROC curve was 0.551 (SE 0.122) and still indicated
no help to differentiate luminal A from luminal B
(Additional file 2: Figure 2).
Sorlie et al. demonstrated that breast cancer can be
classified into 5 different subtypes according to cDNA
molecular profiles, and that these molecular subtypes
significantly influence patient’s prognosis [4]. Subse-
quently, the study of Munoz et al. [25] showed a signifi-
cantly unfavorable prognosis for luminal B patients in
comparison to those with luminal A subtype in terms of
RFI and OS1. Our data confirmed these results. How-
ever, in our study, we did not find different luminal
subtypes predicting the PFS or OS2 after relapse, a
phenomenon which could also be result of transform-
ation of the original HR or HER2 status. Another reason
for this could be a suboptimal accuracy in the measure-
ment of our luminal subtypes, with a sensitivity of 77%
(95% CI, 0.64-0.87) and a specificity of 78% (95% CI,
0.68-0.87) [6]. Hence, it was necessary to explore new
indicator to determine prognosis of the MBC patients
with luminal subtypes, and PET scan was of particular
attraction due to its non-invasive nature.
Our study is one of the first to show that the Baseline
SUVmax of PET scan has significant association with
prognosis and outcome of MBC patients with luminal
subtypes in terms of PFS and OS2, with the multivariate
COX regression analysis confirming the SUVmax an in-
dependent prognostic factor.
Although some studies have examined PET/CT im-
aging as a predictor of treatment response in the
primary breast cancer lesion [26-33], significantly less
is known about how baseline PET/CT imaging can be
used as a prognostic tool by quantifying radiotracer
accumulation in metastases. A very recently published
study showed that only in patients with newly diagnosed
MBC to bone was Baseline SUVmax tertile signifi-
cantly associated with OS on both univariate analysis
(HR = 3.13) and multivariate analysis (HR = 3.19) [34].
However, this study was a retrospective one and did not
focus on the patients with luminal subtypes.
Our study was prospectively performed with important
findings for luminal type breast cancer patients with
newly diagnosed metastases. Baseline SUVmax was
found significantly related to the number of metastatic
sites and presence of visceral metastasis but could not
effectively differentiate patients with luminal A from lu-
minal B subtype. Most importantly, although luminal


















≤ 50 NA† NA† 10.0 0.868 36.5 0.966
> 50 10.9 NR
Menstruation status
Pre-menopausal NA† NA† 9.5 0.985 36.5 0.565
Post-menopausal 11.3 NR
Histology
IDC 31.5 0.550 130.8 0.454 10.4 0.513 36.5 0.560
ILC 36.4 NR 4.4 NR
Others 39.1 72.8 17.2 32.6
Luminal subtype
Luminal A 41.2 <0.001 222.1 0.011 11.6 0.550 36.5 0.233
Luminal B 24.2 71.7 9.4 32.6
Adjuvant/neoadjuvant
therapy
Only CT (± RT) 17.7 0.138 NR 0.927 5.1 0.463 NR 0.639
Only HT (± RT) 17.2 NR 23.2 NR
CT + HT (± RT) 36.1 NR 11.3 NR
Therapy with TT 28.9 NR 8.4 NR
No 28.9 NR 13.7 NR
Relapse-free interval
≤ 2 years NA NA 8.2 0.003 22.8 0.017
> 2 years 12.9 NR
No. of metastatic sites
1 NA NA 13.0 0.002 NR 0.032
2 16.5 32.6
≥ 3 8.4 25.1
Visceral metastasis
Yes NA NA 9.0 0.035 36.5 0.393
No 13.3 NR
First-line therapy after PET/CT
HT NA NA 21.0 0.037 NR 0.019
CT (± TT) 9.5 32.6
Baseline SUVmax
≤ 5.60 (Lowest tertile) NA NA 19.2 0.002 NR 0.009
5.60 ~ 8.70 (Intermediate
tertile)
10.4 35.3
> 8.70 (Highest tertile) 8.2 22.6
RFI: relapse-free interval; OS: overall survival; PFS: progression-free survival; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; CT: chemotherapy; RT:
radiotherapy; HT: hormonal therapy; TT: target therapy; No.: number; SUVmax: the maximum standardized uptake value; NA: not applicable; NR: not reached.
* Log-rank test.
† The data of age and menstruation status were collected after diagnosis of relapse and informed consent obtained. These data were different from those at
diagnosis of primary breast cancer.
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Figure 3 Luminal subtypes and Baseline SUVmax as prognostic variables in survival curves. (A) Relapse-free interval (RFI) curves according
to Luminal types. (B) Overall survival 1 (OS1) curves according to Luminal types. (C) Progression-free survival (PFS) curves according to Luminal
types. (D) Overall survival 2 (OS2) curves according to Luminal types. (E) PFS curves according to Baseline SUVmax tertiles. (F) OS2 curves
according to Baseline SUVmax tertiles.
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from the primary surgery could predict the RFI, it could
not predict PFS or OS2 after developing relapse or me-
tastases. In contrast, Baseline SUVmax as determined on
PET scan was predictive of both PFS and OS. In multi-
variate analysis using COX regression model, the Base-
line SUVmax, RFI, and number of metastatic sites were
three independent prognostic factors for PFS. For OS,
the significant predictors were only Baseline SUVmax
and RFI.
SUV has many drawbacks as it is dependent on
parameters such as the delay between injection and
measurement, plasma glucose concentration, body
weight, instrumental factors and partial volume effect
(PVE) [35]. SUVmax is defined as the SUV derived fromTable 3 Cox regression* results of PFS and OS2
Cox regression results of PFS
Independent prognostic factors Hazard ratio (HR) 95% CI P value
Relapse-free interval
≤ 2 years Ref
> 2 years 0.51 0.34-0.76 0.001
No. of metastatic sites
1 Ref
2 1.00 0.59-1.68 0.993
≥ 3 1.90 1.18-3.08 0.008
Baseline SUVmax
Lowest tertile Ref
Intermediate tertile 1.60 0.97-2.66 0.067
Highest tertile 2.06 1.23-3.45 0.006
Cox regression results of OS2
Independent prognostic factors Hazard ratio (HR) 95% CI P value
Relapse-free interval
≤ 2 years Ref
> 2 years 0.44 0.25-0.78 0.005
Baseline SUVmax
Lowest tertile Ref
Intermediate tertile 2.44 1.12-5.32 0.025
Highest tertile 3.54 1.66-7.55 0.001
* The procedure was carried out with the method of “Forward: LR”.
PFS: progression-free survival; OS: overall survival; CI: confidence interval; No.:
number; SUVmax: the maximum standardized uptake value; Ref:
reference category.the single voxel showing the highest uptake within a
defined region of interest (ROI) or VOI. In the absence
of noise, this SUVmax is indeed the least affected by
PVE and so is often considered the best measure of
tumor uptake. However, in any real imaging situation,
noise is always present, making SUVmax variable. An-
other drawback of SUVmax is that because it is derived
from a single voxel, it may not be an adequate surrogate
marker for true tumor biology and it can be heavily
influenced by voxel size [36]. Use of the maximum pixel
value in a tumor to characterize tumor uptake, however,
does make the measurement independent of the obser-
ver. This is why, despite its sensitivity to noise and voxel
size, the use of SUVmax is still popular.
Several limitations of our study should be addressed.
Firstly, as not all MBC patients in our center underwent
PET/CT imaging, a selection bias may have played a role
in our patients not being representative of general popu-
lation of MBC cases with luminal disease. Secondly,
more than a half of lesions with positive 18 F-FDG up-
take were not biopsied, and thus metastatic disease was
diagnosed only with imaging and long-time clinical
follow-up. Thirdly, not all HER2-positive luminal B
patients received trastuzumab, which may partly influ-
ence applicability of our results to the HER2-positive
cases who will have trastuzumab therapy. Lastly, we
examined PET/CT imaging from only 1 time-point and,
thus, are unable to comment on the predictive effect of
PET/CT imaging with regard to treatment effect.
In spite of these limitations, our study remains the first
to establish the role of PET scanning as a noninvasive
outcome indicator of luminal A versus luminal B MBC
subtypes.Conclusions
We conclude that while the Baseline SUVmax in our
study of MBC did not correlate with molecular subtypes
of primary tumor, the SUVmax, rather than molecular
subtype, emerged as a potential surrogate marker for
survival with metastatic disease. These data indicate a
promise of PET scan use for prognostic assessment of
patients with MBC in general, with future studies
required to clarify the PET scan role in refining, as a
non-invasive procedure, the significance and, ultimately,
individualized therapeutic options for different molecu-
lar subtypes.
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Additional file 1: Figure 1. Summary of molecular subtype differences
between the primary and relapsed or metastatic lesion in 28 patients
with core biopsies after recurrence.
Additional file 2: Figure 2. The receiver operator characteristic (ROC)
curve for SUVmax in the differential diagnosis of luminal A subtype from
luminal B subtype in patients with core biopsies after recurrence (luminal
A, 13; luminal B, 12). The curve describes the association between
sensitivity and specificity at different thresholds. The area under the curve
(AUC) was 0.551.
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